Journal
DRUG DISCOVERY TODAY
Volume 18, Issue 1-2, Pages 43-49Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.07.013
Keywords
-
Categories
Funding
- NIH
- American Lebanese Syrian Associated Charities
- St Jude Children's Research Hospital (SJCRH)
Ask authors/readers for more resources
The identification of potent spliceosome modulators that demonstrate antitumor activity indicates that this complex may be a target for drug development. Several natural products have been demonstrated to bind to the SF3b1 subunit of this macromolecule and these agents modulate alternative RNA splicing. In this article we describe their biological properties, discuss the validity of the spliceosome as a therapeutic target, and propose that alteration of alternative splicing represents a viable approach for inducing tumor-selective cytotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available